Study Stopped
Insufficient patient population
Role of Repeat Resection in Recurrent Glioblastoma
1 other identifier
interventional
N/A
1 country
1
Brief Summary
Patients with recurrent Glioblastoma (GBM) are commonly presented to surgeons, along with the question of whether or not to re-resect the recurrence. There is no Level 1 evidence to support a role for repeat surgery in this context, but a multitude of observational research suggests that repeat surgery may improve quality survival. Unfortunately, these studies all suffer from selection bias. The goal of this study is to provide a care trial context to help neurosurgeons manage patients presenting with recurrent GBM, with no additional risks, tests, or interventions than what they would normally encounter in routine care. Secondary goals include a test of the hypothesis that repeat resection can improve median overall survival, and that it can increase the number of days of survival outside of a hospital/nursing/palliative care facility.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Aug 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 4, 2021
CompletedFirst Posted
Study publicly available on registry
April 9, 2021
CompletedStudy Start
First participant enrolled
August 26, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 24, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 24, 2025
CompletedJuly 8, 2025
July 1, 2025
3.6 years
April 4, 2021
July 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Length of Overall Survival
The primary outcome is time to death from any cause, starting from the time of inclusion.
Follow-up for 5 Years or until death
Secondary Outcomes (5)
Total length of hospitalization / palliative care / nursing home
Follow-up for 5 Years or until death
Discharge to a location other than home
Follow-up for 5 Years or until death
Total number of days spent outside a hospital or nursing care facility.
Follow-up for 5 Years or until death
Incidence of peri-operative non-neurological complications (wound infection, CSF leaks)
Follow-up for 5 Years or until death
Incidence of new significant neurological deficits after surgery (defined as new or substantially worsened aphasia, or new weakness (MRC power < 3 in one or more limbs).
Follow-up for 5 Years or until death
Study Arms (2)
Repeat Surgical Resection
EXPERIMENTALStandard surgical operative management according to local practices.
Management Without Re-operation
ACTIVE COMPARATORNon-surgical management with standard care according to local practices.
Interventions
Routine of surgical operative management. Details of treatment will be left to local centers, and recorded in the case report form (CRF).
Eligibility Criteria
You may qualify if:
- Age ≥ 18
- Previously histologically confirmed and surgically resected Glioblastoma
- Previous craniotomy for open tumor resection (needle biopsies alone do not count as resection)
- The attending surgeon considers re-operation may improve quality survival
You may not qualify if:
- Informed consent not possible
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Alberta Division of Neurosurgery
Edmonton, Alberta, T6G 2B7, Canada
Related Publications (24)
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. doi: 10.1093/neuonc/noz150.
PMID: 31675094BACKGROUNDThakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96. doi: 10.1158/1055-9965.EPI-14-0275. Epub 2014 Jul 22.
PMID: 25053711BACKGROUNDYahia-Cherif, M., De Witte, O., Mélot, C., & Lefranc, F. (2019). P14.56 Recurrent Glioblastomas: Should we operate a second and even a third time. Neuro-Oncology, 21(Suppl 3), iii80.
BACKGROUNDDe Bonis P, Anile C, Pompucci A, Fiorentino A, Balducci M, Chiesa S, Lauriola L, Maira G, Mangiola A. The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg. 2013 Jan;115(1):37-43. doi: 10.1016/j.clineuro.2012.04.005. Epub 2012 Apr 24.
PMID: 22537870BACKGROUNDStupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330.
PMID: 15758009BACKGROUNDWeller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol. 2013 Jan;15(1):4-27. doi: 10.1093/neuonc/nos273. Epub 2012 Nov 7.
PMID: 23136223BACKGROUNDGempt J, Forschler A, Buchmann N, Pape H, Ryang YM, Krieg SM, Zimmer C, Meyer B, Ringel F. Postoperative ischemic changes following resection of newly diagnosed and recurrent gliomas and their clinical relevance. J Neurosurg. 2013 Apr;118(4):801-8. doi: 10.3171/2012.12.JNS12125. Epub 2013 Feb 1.
PMID: 23373806BACKGROUNDBarbagallo GM, Jenkinson MD, Brodbelt AR. 'Recurrent' glioblastoma multiforme, when should we reoperate? Br J Neurosurg. 2008 Jun;22(3):452-5. doi: 10.1080/02688690802182256.
PMID: 18568742BACKGROUNDMandl ES, Dirven CM, Buis DR, Postma TJ, Vandertop WP. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol. 2008 May;69(5):506-9; discussion 509. doi: 10.1016/j.surneu.2007.03.043. Epub 2008 Feb 8.
PMID: 18262245BACKGROUNDChen MW, Morsy AA, Liang S, Ng WH. Re-do Craniotomy for Recurrent Grade IV Glioblastomas: Impact and Outcomes from the National Neuroscience Institute Singapore. World Neurosurg. 2016 Mar;87:439-45. doi: 10.1016/j.wneu.2015.10.051. Epub 2015 Nov 14.
PMID: 26585720BACKGROUNDHervey-Jumper SL, Berger MS. Reoperation for recurrent high-grade glioma: a current perspective of the literature. Neurosurgery. 2014 Nov;75(5):491-9; discussion 498-9. doi: 10.1227/NEU.0000000000000486.
PMID: 24991712BACKGROUNDFranceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer. 2005 Dec 1;104(11):2473-6. doi: 10.1002/cncr.21564.
PMID: 16270316BACKGROUNDGoldman DA, Hovinga K, Reiner AS, Esquenazi Y, Tabar V, Panageas KS. The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis. J Neurosurg. 2018 Nov 1;129(5):1231-1239. doi: 10.3171/2017.6.JNS17393. Epub 2018 Jan 5.
PMID: 29303449BACKGROUNDLu VM, Jue TR, McDonald KL, Rovin RA. The Survival Effect of Repeat Surgery at Glioblastoma Recurrence and its Trend: A Systematic Review and Meta-Analysis. World Neurosurg. 2018 Jul;115:453-459.e3. doi: 10.1016/j.wneu.2018.04.016. Epub 2018 Apr 11.
PMID: 29654958BACKGROUNDZhao YH, Wang ZF, Pan ZY, Peus D, Delgado-Fernandez J, Pallud J, Li ZQ. A Meta-Analysis of Survival Outcomes Following Reoperation in Recurrent Glioblastoma: Time to Consider the Timing of Reoperation. Front Neurol. 2019 Mar 26;10:286. doi: 10.3389/fneur.2019.00286. eCollection 2019.
PMID: 30984099BACKGROUNDHelseth R, Helseth E, Johannesen TB, Langberg CW, Lote K, Ronning P, Scheie D, Vik A, Meling TR. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand. 2010 Sep;122(3):159-67. doi: 10.1111/j.1600-0404.2010.01350.x. Epub 2010 Mar 18.
PMID: 20298491BACKGROUNDRaymond J, Darsaut TE, Altman DG. Pragmatic trials can be designed as optimal medical care: principles and methods of care trials. J Clin Epidemiol. 2014 Oct;67(10):1150-6. doi: 10.1016/j.jclinepi.2014.04.010. Epub 2014 Jul 16.
PMID: 25042688BACKGROUNDPatel M, Au K, Davis FG, Easaw JC, Mehta V, Broad R, Chow MMC, Hockley A, Kaderali Z, Magro E, Nataraj A, Scholtes F, Chagnon M, Gevry G, Raymond J, Darsaut TE. Clinical Uncertainty and Equipoise in the Management of Recurrent Glioblastoma. Am J Clin Oncol. 2021 Jun 1;44(6):258-263. doi: 10.1097/COC.0000000000000812.
PMID: 33782334BACKGROUNDSchucht P. RESURGE: Surgery for recurrent Glioblastoma., https://clinicaltrials.gov/ct2/show/NCT02394626 (2020).
BACKGROUNDSchwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967 Aug;20(8):637-48. doi: 10.1016/0021-9681(67)90041-0. No abstract available.
PMID: 4860352BACKGROUNDRaymond J, Darsaut TE, Roy DJ. Recruitment in Clinical Trials: The Use of Zelen's Prerandomization in Recent Neurovascular Studies. World Neurosurg. 2017 Feb;98:403-410. doi: 10.1016/j.wneu.2016.11.052. Epub 2016 Nov 19.
PMID: 27876665BACKGROUNDChaichana KL, Zadnik P, Weingart JD, Olivi A, Gallia GL, Blakeley J, Lim M, Brem H, Quinones-Hinojosa A. Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg. 2013 Apr;118(4):812-20. doi: 10.3171/2012.9.JNS1277. Epub 2012 Oct 19.
PMID: 23082884BACKGROUNDHoover JM, Nwojo M, Puffer R, Mandrekar J, Meyer FB, Parney IF. Surgical outcomes in recurrent glioma: clinical article. J Neurosurg. 2013 Jun;118(6):1224-31. doi: 10.3171/2013.2.JNS121731. Epub 2013 Mar 15.
PMID: 23495879BACKGROUNDPatel M, Au K, Easaw JC, Davis FG, Young K, Mehta V, Bowden GN, Keough MB, Sankar T, Scholtes F, Chagnon M, L'Esperance G, Yuan Y, Gevry G, Raymond J, Darsaut TE. Repeat resection in recurrent glioblastoma (3rGBM) Trial: A randomized care trial. Neurochirurgie. 2022 Apr;68(3):262-266. doi: 10.1016/j.neuchi.2021.09.001. Epub 2021 Sep 14.
PMID: 34534565DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 4, 2021
First Posted
April 9, 2021
Study Start
August 26, 2021
Primary Completion
March 24, 2025
Study Completion
March 24, 2025
Last Updated
July 8, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF
- Time Frame
- Indefinitely
Data will be made available upon reasonable request.